BioSpace

CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy

At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.

By BioSpace

1 min read
CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights